Southeast Us Renal Disease Market Research Report Forecast to 2027

The renal disease affects the body's ability to clean blood and filter extra water. The two main causes of chronic kidney disease are diabetes and high blood pressure, which are responsible for up to two-thirds of the cases. Diabetes happens when your blood sugar is too high, causing damage to many organs in your body, including the kidneys and heart, as well as blood vessels, nerves and eyes. High blood pressure, or hypertension, occurs when the pressure of your blood against the walls of your blood vessels increases. If uncontrolled, or poorly controlled, high blood pressure can be a leading cause of heart attacks, strokes, and chronic kidney disease. Also, chronic kidney disease can cause high blood pressure.

The scope of the Southeast US renal disease market study includes market size analysis and a detailed analysis of the manufacturer's products and service strategies.

Renal or kidney disease is a condition in which the kidneys cannot function properly, remove waste and extra water from the blood or keep body chemicals in balance. Depending upon the numerous conditions, different types of symptoms, and signs, different types of kidney diseases are formed.

The growth of the Southeast US renal disease market is driven by the increasing cases of diabetes and hypertension and the rising prevalence of chronic kidney disease. Additionally, the growing geriatric population in the Southeast US and rise in government initiatives will provide growth opportunities for the market in the future. However, the risks associated with dialysis procedures and kidney transplantation might hamper the growth of the market in the forecast period.

Market Segmentation

The market is segmented in terms of disease type, treatment type and end user.

The Southeast US renal disease market is segmented based on disease type into chronic kidney disease, end-stage renal disease (ESRD), and others. The other segment includes acute kidney injury, kidney cysts, kidney stones, kidney infections, and proteinuria.

The Southeast US renal disease market is segmented based on treatment type into dialysis, medication, and kidney transplantation. The dialysis segment is further sub-segmented into antihypertensive drugs, erythropoiesis-stimulating agents (ESAs), potassium binders, and phosphate binders. The medication segment is further bifurcated into diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, B blockers, renin inhibitors, vasodilators, and others.

Based on end user, the Southeast US renal disease market is bifurcated into dialysis centers, hospitals & clinics, research and academic institutes, and others. The others segment includes diagnostic centers, home care settings, and others

Major Players

key players contributing to the market growth include Sanofi, Teva Pharmaceuticals, Abbott, GSK, AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Fresenius Medical Care AG & Co. KG F Hoffman-La Roche Ltd, Amgen Inc. Kissie Pharmaceuticals, and Akebia Therapeutics.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: NA

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING CASES OF DIABETES AND HYPERTENSION
- 4.2.2 RISING PREVALENCE OF CHRONIC KIDNEY DISEASE
4.3 RESTRAINT
- 4.3.1 RISKS ASSOCIATED WITH DIALYSIS PROCEDURE AND KIDNEY TRANSPLANTATION
4.4 OPPORTUNITIES
- 4.4.1 GROWING GERIATRIC POPULATION
- 4.4.2 RISE IN GOVERNMENT INITIATIVES
4.5 THREAT
- 4.5.1 SUSTAINABILITY OF SMALL AND MEDIUM-SIZED COMPANIES IN THE MARKET
4.6 TREND
- 4.6.1 TREND OF MEDICAL PRACTICE GROWTH AMONG NEPHROLOGISTS
4.7 NUMBER OF NEPHROLOGISTS CURRENTLY PRACTISING AND NEW GRADUATES GOING INTO THIS SPECIALTY

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 BARGAINING POWER OF SUPPLIERS
- 5.2.2 BARGAINING POWER OF BUYERS
- 5.2.3 THREAT OF NEW ENTRANTS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE SOUTHEAST US RENAL DISEASE MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON ESRD PATIENTS

6 SOUTHEAST US RENAL DISEASE MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 CHRONIC KIDNEY DISEASE
6.3 END-STAGE RENAL DISEASE
6.4 OTHERS

7 SOUTHEAST US RENAL DISEASE MARKET, BY TREATMENT TYPE

7.1 OVERVIEW
7.2 DIALYSIS
7.3 MEDICATION
7.4 KIDNEY TRANSPLANTATION

8 SOUTHEAST US RENAL DISEASE MARKET, BY END USER

8.1 OVERVIEW
8.2 DIALYSIS CENTERS
8.3 HOSPITALS & CLINICS
8.4 RESEARCH AND ACADEMIC INSTITUTES
8.5 OTHERS

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE SOUTHEAST US RENAL DISEASE MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE SOUTHEAST US RENAL DISEASE MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 9.6.2 MERGER &ACQUISITION
- 9.6.3 PARTNERSHIP/AGREEMENT/MARKETING STRATEGY
- 9.6.4 CLINICAL TRIALS
9.7 FINANCIAL MATRIX
- 9.7.1 SALES (USD MILLION), 2020
- 9.7.2 R&D EXPENDITURE (USD MILLION), 2020

10 COMPANY PROFILES

10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS/SERVICES OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 NOVARTIS AG
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS/SERVICES OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 ABBOTT
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS/SERVICES OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
10.4 PFIZER INC.
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS/SERVICES OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 SWOT ANALYSIS
- 10.4.6 KEY STRATEGIES
10.5 GLAXOSMITHKLINE PLC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS/SERVICES OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 KEY STRATEGIES
10.6 SANOFI
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS/SERVICES OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 KEY STRATEGIES
10.7 ASTRAZENECA
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS/SERVICES OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 KEY STRATEGIES
10.8 BRISTOL-MYERS SQUIBB COMPANY
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS/SERVICES OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 F. HOFFMANN-LA ROCHE LTD
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS/SERVICES OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
10.10 AMGEN INC.
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS/SERVICES OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES
10.11 FRESENIUS MEDICAL CARE AG & CO.
- 10.11.1 COMPANY OVERVIEW
- 10.11.2 FINANCIAL OVERVIEW
- 10.11.3 PRODUCTS/SERVICES OFFERED
- 10.11.4 KEY DEVELOPMENTS
- 10.11.5 SWOT ANALYSIS
- 10.11.6 KEY STRATEGIES
10.12 KISSEI PHARMACEUTICAL CO., LTD
- 10.12.1 COMPANY OVERVIEW
- 10.12.2 FINANCIAL OVERVIEW
- 10.12.3 PRODUCTS/SERVICES OFFERED
- 10.12.4 KEY DEVELOPMENTS
- 10.12.5 KEY STRATEGIES
10.13 AKEBIA THERAPEUTICS
- 10.13.1 COMPANY OVERVIEW
- 10.13.2 FINANCIAL OVERVIEW
- 10.13.3 PRODUCTS/SERVICES OFFERED
- 10.13.4 KEY DEVELOPMENTS
- 10.13.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES
11.2 RELATED REPORTS